Home / Biopharma / St. Jude Medical Inc. (NYSE:STJ) Declares Results From Two Cardiovascular Clinical Trials

St. Jude Medical Inc. (NYSE:STJ) Declares Results From Two Cardiovascular Clinical Trials

St. Jude Medical Inc. (NYSE:STJ) [Trend Analysis] hangs on to mix trends, as shares trade at $76.78 by moved up 0.76% with volume of 4.09 Million shares that was impressive than its average volume of 3630.88 shares. St. Jude Medical, Inc. (STJ) released that its results from two cardiovascular clinical trials presented at EuroPCR 2016.

The studies, which include a look at how St. Jude Medical™ fractional flow reserve (FFR) technology impacts patient outcomes in Acute Coronary Syndrome (ACS) and a comparison of left atrial appendage occlusion (LAAO) therapy to standard medical treatment, were presented during hotline sessions.

The latest studies contribute to the growing body of evidence supporting two important St. Jude Medical cardiovascular therapies: FFR guidance with St. Jude Medical PressureWire™ technology to optimize percutaneous coronary intervention (PCI) procedures in patients with narrowed or blocked coronary arteries, as well as left atrial appendage closure for patients at increased risk of stroke as a result of atrial fibrillation.

For current month, 3 analyst from pool recommended for an “overweight” rating, while 3 gave rating of “Buy” and 22 analysts suggest to “Hold” and 1 gave preference to “underweight,” according to research rating by WSJ.

While alarming thing to be notice is price target, the average pool price target for STJ has been mentioned as; 89.00 tends to high price target, medium level touched to 80.00, and 58.00 was assigned as lowest share price targets. To accommodate all of these, average analyst price target appeared by 74.08, where as the current price is 76.78, as per research conducted by WSJ.

As the revenues measures, firm has operation margin of 16.50% in the following twelve months with net profit margin of positive 12.60%. The Company showed a positive 12.60% in the net profit margin and in addition to in its operating margin which remained 16.50%. Company’s annual sales growth for the past five year was 1.40%.

St. Jude Medical Inc. (NYSE:STJ) presented weekly performance of 1.37% with respect to its rate of return and it remained 26.95% for the month. However, the performance for a quarter experienced change of 43.00% and its performance for a year is 4.68% and its year to date performance remained in green with 25.01%. The stock price volatility was 0.83% for a week and 1.13% for a month as well as price volatility’s Average True Range for 14 days was 1.21 and its beta remained 1.26.

Current stock price is in the upbeat territory taking into account of 20 days moving average with 5.29% and continued bullish run for 50 days moving average with 22.29%. Its earnings per share for the past twelve months were -11.10%. Company’s beta coefficient was at 1.26. Beta measures the amount of market risk associated with market trade.


About Devon Leftovich

Check Also

Truces Call By Bulls and Bears: Rigel Pharmaceuticals (NASDAQ:RIGL), Mylan N.V. (NASDAQ:MYL)

Several matter pinch shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) [Trend Analysis], as shares plunging -3.11% to $2.64 …

Leave a Reply

Your email address will not be published. Required fields are marked *